Efficacy and Safety of Intracavernosal Alprostadil in Men with Erectile Dysfunction
Open Access
- 4 April 1996
- journal article
- clinical trial
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 334 (14), 873-877
- https://doi.org/10.1056/nejm199604043341401
Abstract
Erectile dysfunction is a common medical problem affecting many men. Although several intracavernosal therapies are available, their efficacy and safety have not been studied systematically.This publication has 20 references indexed in Scilit:
- Impotence and Its Medical and Psychosocial Correlates: Results of the Massachusetts Male Aging StudyJournal of Urology, 1994
- NIH Consensus Conference. Impotence. NIH Consensus Development Panel on ImpotenceJAMA, 1993
- Predictive Value of Real-Time Rigiscan Monitoring for the Etiology of Organogenic ImpotenceJournal of Urology, 1993
- Nitric Oxide as a Mediator of Relaxation of the Corpus Cavernosum in Response to Nonadrenergic, Noncholinergic NeurotransmissionThe New England Journal of Medicine, 1992
- A nitric oxide-like factor mediates nonadrenergic-noncholinergic neurogenic relaxation of penile corpus cavernosum smooth muscle.JCI Insight, 1991
- ImpotenceThe New England Journal of Medicine, 1989
- Dose‐dependent effect and side‐effect of prostaglandin E1 in erectile dysfunction.British Journal of Clinical Pharmacology, 1989
- Intracavernous Injection of Prostaglandin E1 in Impotent MenJournal of Urology, 1988
- New methods in the diagnosis of impotence: RigiScan® penile tumescence and rigidity monitoring and diagnostic papaverine hydrochloride injectionWorld Journal of Urology, 1987
- Effects of Prostaglandin E1 on Penile Erection and Erectile FailureJournal of Urology, 1987